News Releases

AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry

First plaque tool with prospective outcomes data. Faster, sustained LDL-C control: approximately 50% of patients reached goal by 90 days vs. approximately 35% with CCTA alone.  GAMEFILM data highlight high prevalence of heart disease in retired NFL players, underscoring need for advanced plaque

November 2, 2026

Read More

TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients

Late-Breaking P4 study, simultaneously published in NEJM, shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrating pre-procedural CCTA can guide key PCI planning decisions NAVIGATE-PCI shows Heartflow PCI Navigator drove modifications to stent length and

November 1, 2026

Read More

Heartflow to Report Third Quarter 2026 Financial Results on November 12, 2026

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2026 after market close on Thursday,

October 19, 2026

Read More

Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half

FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting Appropriate Use Criteria for cath lab referrals SAN FRANCISCO, Aug.

August 28, 2026

Read More

Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference

SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing and managing coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Wells Fargo 21 st Annual

August 27, 2026

Read More

Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results for the second quarter ended June 30, 2026. Second Quarter 2026 Highlights Total revenue of $64.1

August 13, 2026

Read More

Heartflow to Report Second Quarter 2026 Financial Results on August 13, 2026

SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the second quarter of 2026 after market close on Thursday, August 13, 2026.

July 23, 2026

Read More

New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management

Heartflow Plaque Staging TM, the only staging tool based on total plaque volume *, is now included with every Heartflow Plaque Analysis Data from over 36,000 patients validate the accuracy, reproducibility and utility of Heartflow Plaque Analysis SAN FRANCISCO, July 09, 2026 (GLOBE NEWSWIRE) --

July 9, 2026

Read More

Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance

SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Total revenue of $52.6 million, a 41%

May 14, 2026

Read More

Heartflow to Report First Quarter 2026 Financial Results on May 14, 2026

SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the first quarter of 2026 after market close on Thursday, May 14, 2026.

April 23, 2026

Read More